# Atlas Was Born This Labor Day Weekend 🚀 | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/378833
- Entity ID: wefunder:feed_item:378833
- Published at: 2026-09-07 16:37:01 UTC
- Updated at: 2026-09-11 03:05:14 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors & Community,This Labor Day weekend, an important part of Sen-Jam’s vision began becoming a working system.Our team used Atlas to organize an initial set of 229 approved small-molecule drugs—representing 26,106 potential two-drug combinations—and connect them with 4,200 measurements across 29 inflammation-related biological targets.This is an important step toward making Sen-Jam’s PAIR combination-development approach computable at scale.What is Atlas being built to do?Atlas asks a practical question:Can two approved drugs work together across complementary inflammation pathways at concentrations realistically achievable in patients?By connecting drug-target activity with human exposure, Atlas is being designed to identify clinically realistic combinations, expose missing evidence and recommend the next experiment required to reduce development risk.Over time, Galaxy will compare Atlas’s predictions with laboratory and clinical outcomes, retain what those results teach us and apply those lessons to future programs.What comes next?We have built an important scientific capability—not yet a validated scientific discovery.Our next steps are to: Add every Sen-Jam drug component to Atlas Test Atlas against our known clinical successes and disappointments without favoring the outcomes Compare its rankings with successful combinations and negative controls Lock the data, rules and thresholds Test a prediction whose answer we do not yet know This milestone brings us closer to our larger vision: learning from every experiment and every patient to help deliver better, more accessible medicines faster.The dream is becoming a working system.Let’s do this.JimThis communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase securities. Any offering will be made only to eligible investors through the applicable offering documents, which should be reviewed carefully before making an investment decision. Forward-looking statements involve risks and uncertainties, and actual results may differ materially.